The chemistry, topography, and wettability of that interface determine how rapidly osteoprogenitor cells attach, proliferate, and deposit mineralized matrix. Albrektsson and Wennerberg (2004) classified surfaces by roughness into smooth (Sa less than 0.5 μm), minimally rough (0.5 to 1.0 μm), moderately rough (1.0 to 2.0 μm), and rough (greater than 2.0 μm), and identified moderately rough surfaces as the topographic sweet spot for bone response.

The clinical implication is straightforward. Surface engineering is not a cosmetic differentiator. It is the primary lever by which manufacturers shorten healing time, expand the indication range to compromised bone, and enable immediate loading protocols that would have been considered experimental two decades ago.

2. Surface Modifications: Subtractive vs. Additive Methods

Surface treatments fall into two broad categories. Subtractive methods remove material to create micro-topography; these include grit blasting, acid etching, and the widely used combination known as SLA (Sandblasted, Large-grit, Acid-etched). Additive methods deposit or grow material on the implant surface; examples include plasma-spraying, anodic oxidation (producing thickened, ion-enriched oxide layers such as TiUnite), and biomimetic coatings such as calcium phosphate or fluoride-modified layers. Both strategies aim to increase the surface area available for cell attachment and to introduce a chemistry that favors osteoblast activity.

3. SLA: The Modern Gold Standard

SLA surfaces are produced by blasting titanium with large-grit corundum particles, followed by acid etching with hot solutions of hydrochloric and sulfuric acids. The result is a dual-scale topography combining micro-scale pits from the blast and sub-micron features from the etch. Roughness (Sa) typically ranges from 1.0 to 2.0 μm, placing SLA squarely in the moderately rough category.

Clinical data on SLA are extensive and mature. Wennerberg and Albrektsson (2009) systematically reviewed surface topography studies and concluded that moderately rough surfaces consistently outperformed smoother machined predecessors in terms of bone-to-implant contact (BIC) and removal torque. SLA implants have demonstrated 10-year survival rates above 95 percent in well-controlled prospective cohorts, establishing the surface family as a benchmark against which newer technologies are compared.

4. SLActive and Hydrophilic Surfaces

SLActive shares the macro and micro topography of SLA but is processed differently in the final step. After acid etching, the implant is rinsed under a nitrogen atmosphere to prevent hydrocarbon contamination and is stored in a sealed glass vial containing isotonic saline. This protocol preserves a clean, high-energy titanium oxide surface that is super-hydrophilic on first contact with blood. Rupp et al. (2014) characterized the physicochemical basis for this enhanced wettability, and Buser et al. (2004) demonstrated histologically that SLActive implants developed significantly greater BIC at 2 and 4 weeks compared with conventional SLA in a human histology model.

Lang et al. (2011) confirmed this early-healing advantage in a human study, while a 2024 evidence-based dentistry assessment of resonance frequency analysis (ISQ) reported comparable secondary stability between SLA and SLActive at 12 weeks. The collective interpretation is that hydrophilic surfaces accelerate early osseointegration but converge with conventional SLA by the time conventional loading is performed. The clinical leverage of SLActive is therefore in the early time window: early loading, compromised hosts, irradiated bone, and Type IV maxillary bone where every percentage point of early BIC matters.

5. Anodized Surfaces: TiUnite and the Phosphate Enrichment Story

Anodic oxidation grows a thickened titanium oxide layer through electrochemical processing. The most clinically established example is TiUnite (Nobel Biocare), which incorporates phosphate ions from the electrolyte into a microporous oxide layer. Sul et al. (2006) compared TiUnite, oxidized magnesium-incorporated, and Osseotite surfaces in animal models and reported favorable bone responses for the anodized phosphate-enriched surface, particularly in early healing. Long-term clinical data on TiUnite-surfaced implants include 10-year survival above 95 percent across multiple cohorts, including patients with diabetes, smokers, and immediately loaded full-arch reconstructions.